These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 29518178)

  • 1. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
    O'Riordan W; McManus A; Teras J; Poromanski I; Cruz-Saldariagga M; Quintas M; Lawrence L; Liang S; Cammarata S;
    Clin Infect Dis; 2018 Aug; 67(5):657-666. PubMed ID: 29518178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Giordano PA; Pogue JM; Cammarata S
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S223-S232. PubMed ID: 30957167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.
    Pullman J; Gardovskis J; Farley B; Sun E; Quintas M; Lawrence L; Ling R; Cammarata S;
    J Antimicrob Chemother; 2017 Dec; 72(12):3471-3480. PubMed ID: 29029278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2020 Aug; 80(12):1247-1258. PubMed ID: 32666425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.
    Kingsley J; Mehra P; Lawrence LE; Henry E; Duffy E; Cammarata SK; Pullman J
    J Antimicrob Chemother; 2016 Mar; 71(3):821-9. PubMed ID: 26679243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
    Overcash JS; Kim C; Keech R; Gumenchuk I; Ninov B; Gonzalez-Rojas Y; Waters M; Simeonov S; Engelhardt M; Saulay M; Ionescu D; Smart JI; Jones ME; Hamed KA
    Clin Infect Dis; 2021 Oct; 73(7):e1507-e1517. PubMed ID: 32897367
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
    Lodise TP; Low DE
    Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone.
    Cho JC; Crotty MP; White BP; Worley MV
    Pharmacotherapy; 2018 Jan; 38(1):108-121. PubMed ID: 29059465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
    Friedland HD; O'Neal T; Biek D; Eckburg PB; Rank DR; Llorens L; Smith A; Witherell GW; Laudano JB; Thye D
    Antimicrob Agents Chemother; 2012 May; 56(5):2231-6. PubMed ID: 22314524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering.
    Bassetti M; Righi E; Pecori D; Tillotson G
    Future Microbiol; 2018 Aug; 13():1081-1094. PubMed ID: 29764190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis.
    Vlachaki I; Vacchelli M; Zinzi D; Falla E; Jiang Y; Mantopoulos T; Nathwani D
    BMC Infect Dis; 2021 Oct; 21(1):1036. PubMed ID: 34610820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical review of delafloxacin: a novel anionic fluoroquinolone.
    Mogle BT; Steele JM; Thomas SJ; Bohan KH; Kufel WD
    J Antimicrob Chemother; 2018 Jun; 73(6):1439-1451. PubMed ID: 29425340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corrado ML
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Bassetti M; Hooper D; Tillotson G
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S233-S240. PubMed ID: 30957169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.
    Righi E; Carnelutti A; Vena A; Bassetti M
    Infect Drug Resist; 2018; 11():479-488. PubMed ID: 29670380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    Huang DB; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Desplats E; Torres A
    Int J Antimicrob Agents; 2018 Aug; 52(2):233-240. PubMed ID: 29783024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.